Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Breakfree-SLE phase 2 study of CD19-directed CAR-T cell therapy in active systemic lupus erythematosus
MOH_2026-03-19_015723Phase 2Recruiting
- Sponsor
- Celgene Corporation
- Start
- Aug 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BMS-986353 in systemic lupus erythematosus (SLE) and lupus nephritis (LN), sponsored by Celgene Corporation. Started Aug 2025; status: recruiting.
02
Drugs
BMS-986353
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on MOH_2026-03-19_015723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-03-19_015723.